Clinical Trials
29 trialsNCT06724926 2026-05-18
Concurrent Azeliragon With Craniospinal Irradiation
NYU Langone Health
Phase 1 Active not recruiting
NCT02359565 2026-05-13
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02192359 2026-05-11
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Active not recruiting
NCT00268385 2026-05-07
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05283109 2026-04-30
ETAPA I
Duke University
Phase 1 Active not recruiting
NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT02381886 2026-04-13
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
NCT03605550 2026-03-27
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Nationwide Children's Hospital
Phase 1 Active not recruiting
NCT05413304 2026-03-24
Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT05610891 2026-03-18
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT05916313 2026-03-17
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT03749187 2026-03-13
PNOC017
University of California, San Francisco
Phase 1 Active not recruiting
NCT03152318 2026-03-04
rQNestin
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03514069 2026-02-19
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03030066 2026-02-04
Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
Daiichi Sankyo
Phase 1 Active not recruiting
NCT03389230 2026-02-04
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT07031765 2025-12-18
Peds CHAMP1ON
University of Florida
Phase 1 Active not recruiting
NCT03500991 2025-12-17
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT04214392 2025-10-06
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02062827 2025-10-02
M032-HSV-1
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT04808245 2025-09-22
INTERCEPT-H3
German Cancer Research Center
Phase 1 Active not recruiting
NCT02191488 2025-09-15
ALA-induced PpIX Fluorescence During Brain Tumor Resection
Dartmouth-Hitchcock Medical Center
Phase 1 Active not recruiting
NCT02208362 2025-09-03
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03657576 2025-08-03
C134-HSV-1
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT03299309 2025-07-09
PRiME
Duke University
Phase 1 Active not recruiting
NCT04160494 2025-05-11
D2C7-IT With Atezolizumab for Recurrent Gliomas
Duke University
Phase 1 Active not recruiting
NCT03598244 2025-04-20
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05561374 2024-11-29
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato, Inc.
Phase 1 Active not recruiting